These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29158900)

  • 41. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients.
    Donadello K; Scolletta S; Taccone FS; Covajes C; Santonocito C; Cortes DO; Grazulyte D; Gottin L; Vincent JL
    J Crit Care; 2014 Feb; 29(1):144-9. PubMed ID: 24120089
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
    Watanabe R; Wada H; Miura Y; Murata Y; Watanabe Y; Sakakura M; Okugawa Y; Nakasaki T; Mori Y; Nishikawa M; Gabazza EC; Shiku H; Nobori T
    Clin Appl Thromb Hemost; 2001 Jul; 7(3):229-33. PubMed ID: 11441985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study.
    Uusitalo-Seppälä R; Huttunen R; Tarkka M; Aittoniemi J; Koskinen P; Leino A; Vahlberg T; Rintala EM
    J Intern Med; 2012 Sep; 272(3):247-56. PubMed ID: 22755554
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activation of the fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison with severe sepsis and septic shock.
    Mavrommatis AC; Theodoridis T; Economou M; Kotanidou A; El Ali M; Christopoulou-Kokkinou V; Zakynthinos SG
    Intensive Care Med; 2001 Dec; 27(12):1853-9. PubMed ID: 11797019
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
    Zhang W; Ling D; Tan J; Zhang J; Li L
    Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome.
    Gando S; Kameue T; Nanzaki S; Nakanishi Y
    Thromb Haemost; 1996 Feb; 75(2):224-8. PubMed ID: 8815564
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combined Biomarkers Predict Acute Mortality Among Critically Ill Patients With Suspected Sepsis.
    Kelly BJ; Lautenbach E; Nachamkin I; Coffin SE; Gerber JS; Fuchs BD; Garrigan C; Han X; Bilker WB; Wise J; Tolomeo P; Han JH;
    Crit Care Med; 2018 Jul; 46(7):1106-1113. PubMed ID: 29912095
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
    Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
    [TBL] [Abstract][Full Text] [Related]  

  • 50. suPAR: The unspecific marker for disease presence, severity and prognosis.
    Eugen-Olsen J; Giamarellos-Bourboulis EJ
    Int J Antimicrob Agents; 2015 Dec; 46 Suppl 1():S33-4. PubMed ID: 26603640
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group.
    Hermans PW; Hibberd ML; Booy R; Daramola O; Hazelzet JA; de Groot R; Levin M
    Lancet; 1999 Aug; 354(9178):556-60. PubMed ID: 10470700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nipple aspirate fluid expression of urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor predicts breast cancer diagnosis and advanced disease.
    Qin W; Zhu W; Wagner-Mann C; Sauter ER
    Ann Surg Oncol; 2003 Oct; 10(8):948-53. PubMed ID: 14527916
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Urokinase-type plasminogen activator and plasminogen-activator-inhibitor type 1 predict metastases in good prognosis breast cancer patients.
    De Cremoux P; Grandin L; Diéras V; Savignoni A; Degeorges A; Salmon R; Bollet MA; Reyal F; Sigal-Zafrani B; Vincent-Salomon A; Sastre-Garau X; Magdelénat H; Mignot L; Fourquet A;
    Anticancer Res; 2009 May; 29(5):1475-82. PubMed ID: 19443353
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibitors of plasminogen activator in neutrophils and mononuclear cells from septic patients.
    Haj MA; Robbie LA; Adey GD; Bennett B
    Thromb Haemost; 1995 Dec; 74(6):1528-32. PubMed ID: 8772232
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in gastric cancer.
    Ho CH; Chao Y; Lee SD; Chau WK; Wu CW; Liu SM
    Thromb Res; 1998 Jul; 91(1):23-7. PubMed ID: 9700849
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study.
    Schmitt FCF; Manolov V; Morgenstern J; Fleming T; Heitmeier S; Uhle F; Al-Saeedi M; Hackert T; Bruckner T; Schöchl H; Weigand MA; Hofer S; Brenner T
    Ann Intensive Care; 2019 Jan; 9(1):19. PubMed ID: 30701381
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation.
    Colucci M; Paramo JA; Collen D
    J Clin Invest; 1985 Mar; 75(3):818-24. PubMed ID: 3920245
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cerebrospinal fluid plasminogen activator inhibitor-1: a prognostic factor in posthaemorrhagic hydrocephalus.
    Hansen A; Whitelaw A; Lapp C; Brugnara C
    Acta Paediatr; 1997 Sep; 86(9):995-8. PubMed ID: 9343282
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
    Castelló R; Estellés A; Vázquez C; Falcó C; España F; Almenar SM; Fuster C; Aznar J
    Clin Chem; 2002 Aug; 48(8):1288-95. PubMed ID: 12142386
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of fibrinolysis in sepsis.
    Gando S
    Semin Thromb Hemost; 2013 Jun; 39(4):392-9. PubMed ID: 23446914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.